Business Standard

Saturday, February 08, 2025 | 03:18 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

DCGI emergency use nod for Covaxin, Corbevax and ZyCoV-D across age groups

Covaxin bags approval for 6-12-year age group, Corbevax for 5-12 group, and ZyCoV-D for 12 years and above

Covid vaccine, covid-19
Premium

Vinay Umarji Ahmedabad
The Drug Controller General of India (DCGI) on Tuesday granted emergency use approvals to COVID-19 vaccines Covaxin, Corbevax and ZyCoV-D.

While the emergency use authorisation (EUA) was granted to Bharat Biotech's Covaxin for the age group of 6-12 years, Biological E's Corbevax bagged the nod for 5-12 years age group and Zydus Lifesciences Ltd.'s ZyCoV-D for 12 years and above.

Despite the EUA, a final decision on rolling out the vaccines will be taken by the government's expert body. Currently, Corbevax for 12-14 years and Covaxin for adolesecents are being administered in the country.

With this approval, Zydus's ZyCoV-D vaccine

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in